{"id":"W4407567762","doi":"10.1007/s13555-025-01357-7","title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; SKiN Health","funders":"Sanofi Genzyme; Genentech; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Moderna; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Kiniksa Pharmaceuticals; Ribon Therapeutics; Sun Pharma; Dermira; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; LEO Pharma; Gilead Sciences; Bausch Health; L'Oreal USA; Sanofi; Celgene; GlaxoSmithKline; Amgen; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Medicine; Meta-analysis; Systemic therapy; Dermatology; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001736931,0.0006718284,0.008650074,0.0007557298,0.0001865384,0.00002579495,0.000281388,0.0007852903,0.0002046998],"category_scores_gemma":[0.00005575784,0.0004799546,0.002939421,0.0008179414,0.0001932993,0.00005378991,0.00004877358,0.0002651733,0.00001273627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002107653,"about_ca_system_score_gemma":0.0003047483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001003267,"about_ca_topic_score_gemma":0.000009296105,"domain_scores_codex":[0.996958,0.0005705943,0.001209348,0.0006441366,0.0001477137,0.0004702077],"domain_scores_gemma":[0.9969448,0.001490582,0.0005042948,0.0007569583,0.0001487325,0.000154562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009232861,0.0004560776,0.001173889,0.04197138,0.7821733,0.0001646079,0.0004845096,0.0001205905,1.705713e-7,0.004672097,0.02056998,0.1472901],"study_design_scores_gemma":[0.00193212,0.00005940362,0.0001680991,0.001804008,0.3122224,0.001187916,0.00001785652,0.00008188216,0.000005413655,0.0004638829,0.6815946,0.0004624251],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002618024,0.9946406,0.001100725,0.000545978,0.000159398,0.002632581,0.0002974298,0.00008209904,0.0002793132],"genre_scores_gemma":[0.006122465,0.9876986,0.0003311471,0.003775215,0.00005165003,0.001119739,0.000270971,0.00005914164,0.0005710999],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6610246,"threshold_uncertainty_score":0.9997652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07042809012567897,"score_gpt":0.3536065433075238,"score_spread":0.2831784531818449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}